258 related articles for article (PubMed ID: 14672400)
1. Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).
Fuchs IB; Landt S; Bueler H; Kuehl U; Coupland S; Kleine-Tebbe A; Lichtenegger W; Schaller G
Breast Cancer Res Treat; 2003 Nov; 82(1):23-8. PubMed ID: 14672400
[TBL] [Abstract][Full Text] [Related]
2. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.
de Korte MA; de Vries EG; Lub-de Hooge MN; Jager PL; Gietema JA; van der Graaf WT; Sluiter WJ; van Veldhuisen DJ; Suter TM; Sleijfer DT; Perik PJ
Eur J Cancer; 2007 Sep; 43(14):2046-51. PubMed ID: 17719768
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart.
Schneider JW; Chang AY; Rocco TP
Semin Oncol; 2001 Oct; 28(5 Suppl 16):18-26. PubMed ID: 11706392
[TBL] [Abstract][Full Text] [Related]
4. From HER2 to herceptin.
Mokbel K; Hassanally D
Curr Med Res Opin; 2001; 17(1):51-9. PubMed ID: 11464447
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
McKeage K; Perry CM
Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
[TBL] [Abstract][Full Text] [Related]
6. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
Slamon DJ; Leyland-Jones B; Shak S; Fuchs H; Paton V; Bajamonde A; Fleming T; Eiermann W; Wolter J; Pegram M; Baselga J; Norton L
N Engl J Med; 2001 Mar; 344(11):783-92. PubMed ID: 11248153
[TBL] [Abstract][Full Text] [Related]
7. Controversies in the use of adjuvant trastuzumab (Herceptin).
Chowdhury S; Pickering L; Ellis P
J Br Menopause Soc; 2006 Dec; 12(4):172-4. PubMed ID: 17178019
[TBL] [Abstract][Full Text] [Related]
8. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.
Ewer MS; O'Shaughnessy JA
Clin Breast Cancer; 2007 Jun; 7(8):600-7. PubMed ID: 17592672
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies.
Smith IE
Anticancer Drugs; 2001 Dec; 12 Suppl 4():S3-10. PubMed ID: 11989525
[TBL] [Abstract][Full Text] [Related]
10. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of trastuzumab.
Jones RL; Smith IE
Expert Opin Drug Saf; 2004 Jul; 3(4):317-27. PubMed ID: 15268649
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer.
Cook-Bruns N
Oncology; 2001; 61 Suppl 2():58-66. PubMed ID: 11694789
[TBL] [Abstract][Full Text] [Related]
14. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.
Yeon CH; Pegram MD
Invest New Drugs; 2005 Oct; 23(5):391-409. PubMed ID: 16133791
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab-based combinations in metastatic breast cancer: how to make a choice.
Jahanzeb M
Clin Breast Cancer; 2003 Apr; 4(1):28-38. PubMed ID: 12744756
[TBL] [Abstract][Full Text] [Related]
16. Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Perik PJ; Lub-De Hooge MN; Gietema JA; van der Graaf WT; de Korte MA; Jonkman S; Kosterink JG; van Veldhuisen DJ; Sleijfer DT; Jager PL; de Vries EG
J Clin Oncol; 2006 May; 24(15):2276-82. PubMed ID: 16710024
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity associated with the use of trastuzumab in breast cancer patients.
Perik PJ; de Korte MA; van Veldhuisen DJ; Gietema JA; Sleijfer DT; de Vries EG
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1763-71. PubMed ID: 18062750
[TBL] [Abstract][Full Text] [Related]
18. Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials.
Sparano JA
Semin Oncol; 2001 Feb; 28(1 Suppl 3):20-7. PubMed ID: 11301371
[TBL] [Abstract][Full Text] [Related]
19. Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?
Ewer MS; Gibbs HR; Swafford J; Benjamin RS
Semin Oncol; 1999 Aug; 26(4 Suppl 12):96-101. PubMed ID: 10482200
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
